AMANDA FOSTER: Open Payments
NPI 1891473690 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,096 in 205 payments from 23 companies in 2025. Trend: 2023 $925 · 2024 $3,550 · 2025 $4,096
Food & beverage: $3,717Education: $379
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 23 | $528 |
| Novartis Pharmaceuticals Corporation | 24 | $478 |
| OPKO Pharmaceuticals, LLC | 25 | $379 |
| Fresenius USA Marketing, Inc. | 20 | $373 |
| Travere Therapeutics, Inc. | 11 | $310 |
| AstraZeneca Pharmaceuticals LP | 12 | $308 |
| Amgen Inc. | 17 | $280 |
| Mallinckrodt Hospital Products Inc. | 14 | $249 |
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $215 |
| Otsuka America Pharmaceutical, Inc. | 9 | $209 |
Products named: TARPEYO, Fabhalta, RAYALDEE, VELPHORO, ACTHAR, Kerendia, LOKELMA, JARDIANCE.
Industry payments across LA — which companies pay providers there.
